Otsuka Pharmaceutical Co., Ltd. (Otsuka) has entered into an asset purchase agreement with Cantargia AB (Cantargia) for the acquisition of assets related to CAN10. CAN10 is an IL-1RAP antibody in development as a drug candidate for the treatment of autoimmune diseases. Through the transaction, Otsuka will acquire the exclusive global rights to develop, manufacture, and commercialize CAN10 and associated assets..

大塚制药株式会社（Otsuka）与Cantargia AB（Cantargia）达成了一项资产购买协议，收购与CAN10相关的资产。CAN10是一种正在开发中的IL-1RAP抗体，作为治疗自身免疫性疾病的候选药物。通过此次交易，大塚将获得CAN10及其相关资产的全球独家开发、生产和商业化权利。

CAN10 is a monoclonal antibody that targets IL-1RAP (

CAN10是一种单克隆抗体，靶向IL-1RAP（

rotein). IL-1 family cytokines, IL-1, IL-33, and IL-36, which play crucial roles in inflammatory responses, bind to their respective receptors and interact with IL-1RAP to transmit inflammatory signals into cells. These cytokines work together to worsen disease progression of autoimmune diseases. CAN10, as an IL-1RAP antibody, is expected to become a next-generation antibody drug that inhibits the interaction between IL-1RAP and these cytokines, thereby simultaneously blocking signaling of these IL-1 family cytokines.

白细胞介素-1家族细胞因子，包括IL-1、IL-33和IL-36，它们在炎症反应中起关键作用，通过与其各自受体结合并与IL-1RAP相互作用，将炎症信号传递到细胞内。这些细胞因子协同作用，加剧自身免疫性疾病的进展。CAN10作为一种IL-1RAP抗体，有望成为下一代抗体药物，通过抑制IL-1RAP与这些细胞因子的相互作用，同时阻断这些IL-1家族细胞因子的信号传导。

Cantargia is currently conducting Phase 1 trials (NCT06143371) to evaluate the safety and tolerability of CAN10 in healthy subjects, and has demonstrated the inhibition of IL-1β and IL-36 signals. Otsuka plans to continue developing CAN10 for the treatment of autoimmune diseases..

Cantargia目前正在开展1期临床试验（NCT06143371），以评估CAN10在健康受试者中的安全性和耐受性，并已证明对IL-1β和IL-36信号的抑制作用。大冢计划继续开发CAN10用于治疗自身免疫性疾病。

Based on this agreement, Otsuka will pay Cantargia U.S. $33 million upon closing and, future additional contingent payments. The completion of the transaction is subject to obtaining customary regulatory clearances.

基于该协议，大冢将在交易完成时向Cantargia支付3300万美元，并在未来支付额外的附加款项。本次交易的完成需取得常规的监管批准。

Makoto Inoue, president and representative director of Otsuka Pharmaceutical Co., Ltd. commented, 'Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our U.S. subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our U.S.

大塚制药株式会社社长兼代表董事井上真人评论道：“大塚制药正在通过美国子公司Visterra的抗体药物平台和美国的低分子量药物发现平台，扩展自身在自身免疫疾病领域的研发管线。”

subsidiary Jnana Therapeutics. This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients.'.

子公司Jnana Therapeutics。这将进一步扩展和加速我们针对与自身免疫疾病相关的各种通路的研发组合，使我们能够为更多患者的生活做出贡献。”

Cantargia's Interim Chief Executive Officer Damian Marron commented, 'This is a transformative transaction for Cantargia and we hope for millions of patients suffering from severe immune inflammatory disorders.' said Cantargia's Chief Executive Officer Damian Marron. 'We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical.

坎塔吉亚临时首席执行官达米安·马伦评论道：“这对坎塔吉亚来说是一次变革性的交易，我们希望可以惠及数百万患有严重免疫炎症疾病的患者。” 坎塔吉亚首席执行官达米安·马伦表示：“我们很高兴我们的CAN10抗IL1RAP抗体的强大潜力得到了大冢制药的认可。”

It demonstrates confidence in the strength of our world leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases.'.

它证明了我们对在IL1RAP生物学和抗体领域世界领先地位的实力充满信心，并将使我们能够推动我们在肿瘤学和其他疾病领域的平台和项目。

Regarding Cantargia's IL-1RAP antibody portfolio

关于Cantargia的IL-1RAP抗体组合

Cantargia is engaged in the research and development of multiple antibodies that inhibit IL-1RAP. Through this transaction, Otsuka will acquire CAN10, as well as 3G5* as a backup antibody. Additionally, for a specified period following the closing of the transaction, Otsuka will have exclusive first rights of negotiation regarding the next-generation IL-1RAP antibodies to be developed by Cantargia for a period of 2 years.

Cantargia 从事多个抑制 IL-1RAP 的抗体的研究与开发。通过此次交易，大冢制药将获得 CAN10，以及作为备用抗体的 3G5*。此外，在交易完成后的特定期限内，大冢制药将拥有对 Cantargia 在未来两年内开发的下一代 IL-1RAP 抗体的独家优先谈判权。

Note that Cantargia retains all rights to Nadunolimab (CAN04), which it is developing for cancer treatment indications..

请注意，Cantargia保留了其正在开发用于癌症治疗的Nadunolimab（CAN04）的所有权利。

*3G5 is a pre-clinical IL1RAP targeting antibody which is similar to CAN10.

*3G5是一种针对IL1RAP的临床前抗体，与CAN10类似。

About Cantargia

关于Cantargia

Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. It is a leading company in the development of antibodies targeting IL-1RAP. The company is listed on OMX Stockholm's Main List. For further information, please visit .

Cantargia是一家瑞典生物技术公司，专注于开发针对各种类型癌症和炎症/自身免疫性疾病的药物。它是开发靶向IL-1RAP抗体的领先公司。该公司在OMX斯德哥尔摩主板上市。欲了解更多信息，请访问 。

About Otsuka

关于大塚制药

Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement.

大塚制药株式会社是一家全面关注个人潜能提升健康的医疗保健公司。我们的医药相关业务提供身体和心理健康方面的治疗和诊断。我们的营养保健品业务则支持日常健康维护与改善。